Show simple item record

dc.contributor.authorMedrano, Luz Maria 
dc.contributor.authorBerenguer, Juan
dc.contributor.authorSalgüero Fernández, Sergio 
dc.contributor.authorGonzález-García, Juan
dc.contributor.authorDíez, Cristina
dc.contributor.authorHontañón, Víctor
dc.contributor.authorGarcia-Broncano, Pilar 
dc.contributor.authorIbañez-Samaniego, Luis
dc.contributor.authorBellón, José M
dc.contributor.authorJimenez-Sousa, Maria Angeles 
dc.contributor.authorResino, Salvador 
dc.date.accessioned2021-03-09T09:33:23Z
dc.date.available2021-03-09T09:33:23Z
dc.date.issued2021-02
dc.identifier.citationFront Med (Lausanne) . 2021 Feb 1;8:615342.es_ES
dc.identifier.issn2296-858Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/12153
dc.description.abstractBackground: Eradication of hepatitis C virus (HCV) promotes an improvement in liver disease and the deactivation of the immune system. Here, we aimed to evaluate the changes in liver disease scores and plasma biomarkers following HCV clearance with direct-acting antivirals (DAAs) in HIV-infected patients with advanced HCV-related cirrhosis. Methods: We performed an observational study of 50 patients with advanced cirrhosis who received DAAs therapy. Variables were assessed at baseline and 48 weeks after HCV treatment completion. Epidemiological and clinical data were collected through an online form. Liver stiffness measurement (LSM), hepatic venous pressure gradient (HVPG), and Child-Pugh-Turcotte (CTP) were evaluated by physicians. Plasma biomarkers were measured by multiplex immunoassay. Results: We found significant decreases in severity scores of liver disease [LSM (q-value < 0.001), HVPG (q-value = 0.011), and CTP (q-value = 0.045)] and plasma biomarkers [LBP (q-value < 0.001), IP-10 (q-value < 0.001), IL-8 (q-value < 0.001), IL-18 (q-value < 0.001), IL-1RA (q-value = 0.013), OPG (q-value < 0.001), sVCAM-1 (q-value < 0.001), sICAM-1 (q-value < 0.001), PAI-1 (q-value = 0.001), and VEGF-A (q-value = 0.006)]. We also found a significant direct association between the change in LSM values and the change in values of LBP (q-value < 0.001), IP-10 (q-value < 0.001), MCP-1 (q-value = 0.008), IL-8 (q-value < 0.001), IL-18 (q-value < 0.001), OPG (q-value = 0.004), sVCAM-1 (q-value < 0.001), sICAM-1 (q-value < 0.001), and PAI-1 (q-value = 0.002). For CTP values, we found significant positive associations with IP-10 (q-value = 0.010), IL-6 (q-value = 0.010), IL-1RA (q-value = 0.033), and sICAM-1 (q-value = 0.010). Conclusion: The HCV eradication with all-oral DAAs in HIV/HCV-coinfected patients with advanced cirrhosis promoted an improvement in the severity of advanced cirrhosis and plasma biomarkers (inflammation, coagulopathy, and angiogenesis). The decrease in plasma biomarkers was mainly related to the reduction in LSM values.es_ES
dc.description.sponsorshipThis study was supported by grants from Instituto de Salud Carlos III (ISCII; Grant Numbers PI20/00474 and PI17/00657 to JB, PI20/00507 and PI17/00903 to JG-G, CP17CIII/00007 and PI18CIII/00028 to AJ-S, and PI20CIII/00004 and PI17CIII/00003 to SR). The study was also funded by the RD16CIII/0002/0002, RD16/0025/0017, and RD16/0025/0018 projects as part of the Plan Nacional R + D + I and cofunded by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Refs INT16/00100.es_ES
dc.language.isoenges_ES
dc.publisherFrontierses_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHIV/HCV co-infected patientses_ES
dc.subjectAngiogenesises_ES
dc.subjectChronic hepatitis C (CHC)es_ES
dc.subjectCirrhosises_ES
dc.subjectCoagulopathyes_ES
dc.subjectDirect-acting antiviral (DAA) therapyes_ES
dc.subjectInflammationes_ES
dc.titleSuccessful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID33598470es_ES
dc.format.volume8es_ES
dc.format.page615342es_ES
dc.identifier.doi10.3389/fmed.2021.615342es_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fmed.2021.615342es_ES
dc.identifier.journalFrontiers in medicinees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI20/00474es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17/00657es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI20/00507es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17/00903es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CP17CIII/00007es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI18CIII/00028es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI20CIII/00004es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17CIII/00003es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD16CIII/0002/0002es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD16/0025/0018es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional